A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

April 16, 2024

Study Completion Date

May 15, 2024

Conditions

Healthy Participants

Interventions

DRUG

Ruxolitinib IR

Tablet

DRUG

Ruxolitinib XR

Tablet

Trial Locations (1)

Celerion, Inc, Lincoln